CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
Atezolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03102242
NCT03102242Phase 2Completed
CompareCT.gov

Phase II Trial of Induction Immunotherapy With Atezolizumab for Patients With Unresectable Stage IIIA and IIIB NSCLC Eligible for Chemoradiotherapy With Curative Intent.

Alliance Foundation Trials, LLC.·interventional·Posted Apr 5, 2017·Updated May 24, 2023

In Brief

A Phase 2 clinical trial evaluating Atezolizumab for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 64 participants across 13 sites.

Detailed Summary

Phase II trial of induction immunotherapy with atezolizumab for patients with unresectable stage IIIA and IIIB NSCLC eligible for chemoradiotherapy with curative intent.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 5, 2017
Enrollment StartNov 1, 2017
Primary CompletionJun 1, 2020
Study CompletionOct 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 9.2 years ago

Interventions

Atezolizumabdrug

Single arm phase II trial of induction immunotherapy with anti-PD-L1 for patients with unresectable stage III NSCLC and PS 0-1.